Pharmafile Logo
Pharmafocus logo
Advanced Search

MSD

Showing 15 posts of 247 posts found.

keytruda1

NICE knocks back MSD’s Keytruda for lung cancer indication

February 28, 2017
Research and Development, Sales and Marketing MSD, NICE, NSCLC, keytruda

MSD’s immunotherapy drug Keytruda (pembrolizumab) has been knocked back by the National Institute of Health and Care Excellence (NICE) for …

News
merckincweb1

MSD’s investigational cytomegalovirus treatment shows significant promise in Phase 3 trial

February 27, 2017
Research and Development, Sales and Marketing MSD, cytomegalovirus, letermovir

MSD has lifted the curtain on strong Phase 3 results in the development of its investigational antiviral drug letermovir, showing …

News
pharmafocus_march_cover

The March 2017 issue of Pharmafocus is now live!

February 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, FDA, Johnson & Johnson, MSD, Roche, Trump, crispr, immunotherapy, opdivo

The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing …

News
merck_entrance

MSD’s Alzheimer’s drug failure undermines potential treatment pathway

February 15, 2017
Research and Development Alzheimer's, MSD, Merck

MSD, known as Merck in North America, has announced that it has been forced to cancel a Phase 2/3 trial …

News
keytruda3-web

MSD aims to get the jump on BMS treating bladder cancer

February 6, 2017
Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, MSD, keytruda, opdivo

Bristol-Myers Squibb’s Opdivo was only just approved for second-line treatment of bladder cancer, but MSD has attempted to have its …

News

FDA clears Opdivo to treat most common form of bladder cancer

February 6, 2017
Sales and Marketing BMS, Bristol-Myers Squibb, MSD, bladder cancer, immunotherapy, keytruda, opdivo

Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …

News
msd_merck_night_building

MSD’s drug given European approval for first-line treatment in NSCLC

February 1, 2017
Sales and Marketing European Commission, MSD, Merck

The good news keeps coming for MSD, known as Merck in North America, and Keytruda, with a further label expansion …

News
msd

MSD puts best foot forward in drug pricing debate

January 30, 2017
Medical Communications, Sales and Marketing Drug pricing, MSD, Merck

MSD, known as Merck in North America, has taken a pre-emptive step in the drug pricing debate by releasing its …

News

BMS receives $625 million patent settlement boost from Merck

January 23, 2017
Sales and Marketing BMS, MSD, Merck, keytruda, opdivo

Bristol-Myers Squibb were in desperate need of releasing good news after the brief announcement that it would no longer be …

News
access_accelerated

22 pharma companies join forces for global non-communicable disease initiative

January 18, 2017
Research and Development BMS, Celgene, Eisai, Eli Lilly, GSK, J&J, JJ, MSD, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda

The World Economic Forum Annual Meeting in Switzerland has seen the launch of Access Accelerated, a global initiative consisting of …

News

MSD and Lilly announce immuno-oncology collaboration

January 11, 2017
Medical Communications, Research and Development Eli Lilly, Lartruvo, MSD, keytruda, lilly

MSD, known as Merck in North America, and Eli Lilly have announced the expansion of their existing immuno-oncology collaboration. The …

News
merck_and_co

MSD looks to jump the gun with combination immunotherapy application

January 11, 2017
Research and Development, Sales and Marketing AstraZeneca, BMS, MSD, Roche, immunotherapy, keytruda

MSD, known as Merck in North America, has launched a bold move by filing Keytruda, and being accepted, for Priority …

News
syringe

Sanofi and MSD end their joint vaccines partnership

January 3, 2017
Research and Development MSD, Sanofi, Sanofi pasteur msd

With a new year comes a fresh start, and so it was the case with Sanofi and MSD’s joint vaccine …

News
merckincweb1

NICE approves MSD’s Keytruda for new cancer indication

December 1, 2016
Medical Communications, Sales and Marketing MSD, NICE, keytruda

The National Institute of Health and Care Excellence (NICE) has announced its recommendation of MSD’s immunotherapy drug Keytruda (pembrolizumab) for …

News
msd

Powerful new data for MSD’s bladder cancer drug stops trial early

November 16, 2016
Research and Development MSD, pembrolizumab

MSD has released new data which reinforces the efficacy of its anti-PD-1 therapy pembrolizumab in patients with advanced urothelial (bladder) …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026